Introduction
============

Atherosclerosis (AS) is a serious disease that causes hypoxic ischemia of the heart and leads to disordered collagen metabolism during its progression ([@b1-mmr-21-03-1097],[@b2-mmr-21-03-1097]). Multiple studies have revealed that the urotensin II/urotensin report (UII/UT) system, which is composed of UII and its receptor, G protein-coupled receptor 14 (GPR14), serves an important role in various diseases, including AS and heart disease ([@b3-mmr-21-03-1097],[@b4-mmr-21-03-1097]). Therefore, the prevention and treatment of AS via regulation of the UII/UT system may prove to be effective for the improvement of myocardial collagen metabolism disorders.

The Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway is a key cytokine signaling pathway that regulates various pathophysiological processes, including inflammation and myocardial fibrosis ([@b5-mmr-21-03-1097]--[@b7-mmr-21-03-1097]). In addition, the proteolytic enzymes matrix metalloproteinase (MMP) and tissue inhibitor of matrix metalloproteinase can regulate the expression of collagen, which serves an important role in myocardial fibrosis and cardiac dysfunction ([@b8-mmr-21-03-1097]). Study has reported that the JAK2/STAT3 pathway, MMP-2 and MMP-9 are strongly associated with the prevention of myocardial injury by reducing inflammation and fibrosis ([@b9-mmr-21-03-1097]). In the present study, the state of collagen metabolism disorders was monitored in rats with AS by observing changes in the JAK2/STAT3 pathway and the MMP-2/TIMP metallopeptidase inhibitor 2 (TIMP-2) protein ratio.

Urantide, a UII receptor antagonist derived from human UII (hUII), competitively antagonizes the contraction of the rat thoracic aorta and the mitogenic effect of UII on vascular smooth muscle cells ([@b10-mmr-21-03-1097],[@b11-mmr-21-03-1097]). The main reason for conducting the present study was the fact that little research regarding the association between the effects of urantide on the prevention and treatment of AS and AS-related heart disease has been performed. Based on the successful replication of an AS rat model, it was demonstrated that urantide was able to significantly reduce myocardial fibrosis in rats with AS. This effect may have been associated with the JAK2/STAT3 pathway and the MMP-2/TIMP-2 protein ratio.

Materials and methods
=====================

### Animals and treatment groups

A total of 200 Wistar male rats (age, 4 weeks) weighing 180--200 g were obtained from Charles River Laboratories, Inc. and housed at a constant temperature of 22±2°C with a humidity of 40--60% and under a 12-h light/dark cycle. The rats were randomly divided into two groups: A normal control group consisting of 40 rats and an AS model preparation group consisting of 160 rats. Rats in the normal control group were supplied with normal feed daily and rats in the AS model preparation group followed a high-fat diet according to an AS rat preparation method, as previously described ([@b12-mmr-21-03-1097],[@b13-mmr-21-03-1097]). The high-fat diet was purchased from Beijing Keao Xieli Feed Co., Ltd. The experimental period lasted 4 weeks.

An AS rat model was established by intraperitoneal (i.p.) injection of 150 U/kg vitamin D~3~ (Harbin Huasheng Science and Technology Animal Medicine Factory) for 3 days, and rats were continuous feeding a high-fat diet to damage the arterial intima ([@b14-mmr-21-03-1097]). In the fourth week, 10 rats from each of the two experimental groups were randomly sacrificed by i.p. injection of sodium phenobarbital (150 mg/kg) in order to detect whether the AS rat model had been successfully replicated. Subsequently, the rats with AS were randomly divided into the following groups: i) An AS model group (30 rats); ii) a simvastatin group (30 rats); and iii) three urantide groups (30 rats in each of the three subgroups). Saline (30 µg/kg) was injected into the tail veins of rats in the normal control group and the AS model group for 14 consecutive days. Rats in the simvastatin group were intraperitoneally injected with 5 µg/kg simvastatin (Lunan Beite Pharmaceutical Co., Ltd.) for 14 days. Urantide (30 µg/kg; Shanghai Qiangyao Biological Technology Co., Ltd.) was injected into the tail veins of rats with AS in the three urantide groups daily for 3, 7 and 14 days, respectively. In the present study, the dosages of simvastatin and urantide were based on two preliminary studies by Zhao *et al* ([@b10-mmr-21-03-1097],[@b11-mmr-21-03-1097]). The rats were given *ad libitum* access to food and water. The experimental design is presented in [Fig. 1](#f1-mmr-21-03-1097){ref-type="fig"}.

### Sample collection and testing

All rats were sacrificed using 150 mg/kg sodium pentobarbital (Tianjin Fuchen Chemical Co., Ltd.). The rat abdominal aortas were punctured to obtain blood, and following centrifugation at 1,500 × g for 10 min at 4°C, the supernatant was stored at −20°C. In the present study, automated biochemical analysis (BS-480; Shenzhen Mindray Bio-Medical Electronics Co., Ltd.) at Hebei Province 266 Hospital was performed to determine triglyceride (TG), total cholesterol (TC), low-density lipoprotein (LDL), high-density lipoprotein (HDL) and calcium (Ca^2+^) levels.

### Morphological evaluation

The thoracic aortas and hearts were dissected from the rats and divided into two parts; one part was fixed with 4% paraformaldehyde at 4°C for 24 h for morphological examination, while the other part was stored directly in liquid nitrogen for molecular biological detection.

Paraffinized, 4.5-µm sections of rat thoracic aortas and cardiac tissue were prepared and hematoxylin and eosin (H&E) staining (Nanchang Yulu Experimental Equipment Co., Ltd.) was performed according to the manufacturer\'s instructions. A total of 10 heart sections were randomly selected from each group. Each section was examined for evidence of mononuclear and polymorphic cell infiltration, necrosis and mineralization and given a histological score of 0 to 4 as follows: i) 0, no change; ii) 1, changes found in 0--25% of cells; iii) 2, changes found in 26--50% of cells; iv) 3, changes found in 51--75% of cells; and v) 4, changes found in 76--100% of cells ([@b15-mmr-21-03-1097]).

### Masson trichrome staining and immunolocalization

Collagen content in the cardiac tissue was determined using Masson trichrome staining (Fuzhou Maixin Biotech Co., Ltd.). The ratio of collagen positive area to total area was calculated using a computer imaging system. The distribution of phosphorylated (p)-JAK2 (cat. no. ab32101; Abcam), p-STAT3 (phosphorylated-STAT3; cat. no. 9145; Cell Signaling Technology, Inc.) and collagen type I/III (cat. no. bs-0578R/0948R; Bioss) proteins was determined using immunofluorescence. The isolated paraffinized heart sections were dewaxed by xylene, and following their dehydration, stained for collagen at 22±2°C for 5 min and incubated with antibodies against p-JAK2 (cat. no. ab32101; Abcam) and p-STAT3 (cat. no. 9145; Cell Signaling Technology, Inc.) and collagen type I/III (cat. no. bs-0578R/0548R; BIOSS) at 1:300 at 4°C for 12 h according to a standard protocol ([@b16-mmr-21-03-1097]). Next, the sections which were immunoblotted for p-JAK2/p-STAT3 and collagen type I/III were incubated with FITC-labeled goat anti-rabbit IgG antibody (cat. no. A0562; Beyotime Institute of Biotechnology) at 1:1,000 at 37°C for 60 min. Then, the myocardial collagen volume (%) was calculated using Image-Pro Plus 6.0 software (Media Cybernetics, Inc.). Images were captured using a fluorescence microscope (Olympus Corporation).

### Quantification of mRNA expression levels by reverse transcription-quantitative PCR (RT-qPCR)

Total RNA was extracted from the cardiac tissues using TRIzol^®^ reagent (Invitrogen; Thermo Fisher Scientific, Inc.) and quantified by UV spectrophotometry. Subsequently, total RNA was reverse transcribed into cDNA using a FastQuant RT kit (Tiangen Biotech Co., Ltd.) at 42°C for 15 min and 95°C for 3 min. qPCR was subsequently performed using the SuperReal PreMix Plus (SYBR Green) fluorescence quantitative premixing kit (Tiangen Biotech Co., Ltd.). The related gene primers were synthesized by Takara Biotechnology Co., Ltd. and their respective sequences are presented in [Table I](#tI-mmr-21-03-1097){ref-type="table"}. According to the manufacturer\'s protocol, the following thermocycling conditions were used for qPCR: 95°C for 15 min, followed by 40 cycles of 95°C for 10 sec and 60°C for 32 sec. mRNA expression levels were quantified using the 2^−ΔΔCq^ method and normalized to the internal reference gene β-actin ([@b17-mmr-21-03-1097],[@b18-mmr-21-03-1097]).

### Western blot analysis

Western blotting was conducted to evaluate cardiac protein expression. Total protein was extracted from the heart tissue using RIPA protein lysate (Beijing Solarbio Science & Technology Co., Ltd.). Protein content was quantified using the bicinchoninic acid Protein Concentration assay kit (Beijing Solarbio Science & Technology Co., Ltd.). A total of 45 µg protein/lane was separated via 8% SDS-PAGE and transferred to an immobilon-P PVDF membrane, which was blocked with 5% skimmed milk powder at 22±2°C for 1.5 h. Next, the membrane was incubated with primary antibodies against UII (cat. no. orb352970; Biorbyt Ltd.), GPR14 (cat. no. sc-514460; Santa Cruz Biotechnology, Inc.) and p-STAT3 (cat. no. 9145; Cell Signaling Technology, Inc.) at a 1:800 dilution; JAK2 and STAT3 (cat. nos. 380903 and 310003; <http://www.zen-bio.cn/>; Zen Bioscience) at a 1:500 dilution; p-JAK2 (cat. no. ab32101; Abcam) and MMP-2/TIMP-2 (cat. no. BS1236/1366; <https://www.bioworlde.com/Search.aspx?keyword=1366&Category=233&x=7&y=10>; Bioworld Technology, Inc.) at a 1:1,000 dilution; collagen type I/III (cat. no. bs-0578R/0548R; Bioss) at a 1:500 dilution; or GAPDH (cat. no. bs-10900R; Bioss) at a 1:1,000 dilution at 4°C for 14--16 h. The membranes were washed with TBST (0.1% Tween-20; Beijing Solarbio Science & Technology Co., Ltd.) three times and then incubated with horseradish peroxidase-labeled goat anti-rabbit or anti-mouse secondary antibodies (cat. no. 074-1056/074-1086; KPL, Inc.) at a 1:5,000 dilution at room temperature for 1 h. Protein bands were visualized using a hypersensitive ECL chemiluminescence kit (Beyotime Institute of Biotechnology). The intensities of each protein band were analyzed using Image-Pro Plus software (version 6.0; Media Cybernetics, Inc.) with GAPDH as the loading control.

### Statistical analysis

Data are expressed as the mean ± SEM of the mean of ≥3 independent experiments and were analyzed using SPSS software (version 20; IBM Corp.). The serum index contents, and gene and protein expression levels in each group of rats were analyzed by one-way analysis of variance followed by Tukey\'s post hoc test. Cardiac injury scores were analysed by Friedman followed by Nemenyi post hoc test for multiple comparisons. GraphPad Prism (version 7; GraphPad Software, Inc.) software was used to generate the charts. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Assessing the rat model of AS

After 4 weeks, the thoracic aortas dissected from rats in the AS model preparation group were found to contain diverse characteristics typical of AS lesions, in contrast to the thoracic aortas of rats in the normal control group. These characteristics included: i) Intimal inflammatory cell infiltration; ii) obvious calcification; iii) vascular smooth muscle cell proliferation and disorder; iv) foam-like cell formation; v) elastic fiber degeneration; and vi) rupture and disintegration. The specific results from H&E staining are presented in [Fig. 2](#f2-mmr-21-03-1097){ref-type="fig"}.

### Blood lipid and Ca^2+^levels

Compared with the levels in the normal group, the serum TG, TC, LDL and Ca^2+^ levels in the AS model preparation group were significantly increased, whereas HDL levels were decreased. Furthermore, the serum TG, TC, LDL and Ca^2+^ levels in the simvastatin and urantide groups were obviously decreased, in contrast to the HDL content, which was significantly increased. It was revealed that urantide and simvastatin significantly improved blood lipid and Ca^2+^ levels in rats with AS. The specific results are displayed in [Table II](#tII-mmr-21-03-1097){ref-type="table"}.

### Cardiac pathological changes in rats with AS

Morphological methods were employed to assess AS-related cardiac damage and collagen metabolism. In the normal group, neatly arranged myocardial fibers, oval-shaped and centered nuclei, no atrophy or hypertrophy of the myocardial cells, and the microscopic expression of collagen fibers were observed. By contrast, the AS model preparation group exhibited cardiomyocyte hypertrophy, interstitial fibrosis, increased neutrophil infiltration between cells, scattered foam-like cell formation, hyperemia and abundant fibers ([Fig. 3A and B](#f3-mmr-21-03-1097){ref-type="fig"}). Furthermore, both cardiac damage scores and myocardial collagen volumes were significantly higher in the AS model group than in the control group ([Fig. 3C and D](#f3-mmr-21-03-1097){ref-type="fig"}). Compared with the AS model group, the simvastatin and urantide groups were shown to have significantly reduced cardiomyocyte fibrosis and neutrophil infiltration, and lower cardiac injury scores and myocardial collagen volumes. In addition, these improvements were positively associated with treatment time and the effect of 14-day urantide treatment was similar to that observed in the positive control group.

### Alterations in the expression levels of genes and proteins in cardiac tissue

Molecular biology techniques were used to detect gene and protein expression in cardiac tissue. Compared with that in the normal group, the expression of UII, GPR14, JAK2, STAT3, MMP-2 and collagen type I/III was higher in the cardiac tissue of the AS model group, whereas TIMP-2 expression was lower. Furthermore, the expression levels of UII, GPR14, JAK2, STAT3, MMP-2 and collagen type I/III were downregulated in the cardiac tissue of rats in the urantide groups compared with the AS model group; however, TIMP-2 expression was upregulated ([Fig. 4A and B](#f4-mmr-21-03-1097){ref-type="fig"}). Most importantly, when the rats with AS received treatment, the protein ratio of p-JAK2/JAK2, p-STAT3/STAT3 and MMP-2/TIMP-2 was effectively improved as the corresponding protein ratio decreased after urantide treatment ([Fig. 4Ba and C](#f4-mmr-21-03-1097){ref-type="fig"}). Moreover, improved myocardial collagen metabolism was positively associated with the urantide treatment time and the effects of urantide were similar to those of the positive control drug. The specific results are shown in [Fig. 4](#f4-mmr-21-03-1097){ref-type="fig"}. However, the protein ratio of p-JAK2/JAK2 fluctuated at different times of urantide treatment, and the trend was consistent with serological indicators. In addition, simvastatin had little effect on the protein ratio of p-JAK2/JAK2 and p-STAT3/STAT3, as opposed to urantide treatment. Therefore, the specific mechanism underlying these effects require further study.

### Localization of p-JAK2/p-STAT3 and collagen type I/III expression in cardiac tissue

Localization of the p-JAK2/p-STAT3 and collagen type I/III proteins was determined by immunofluorescence. The expression of p-JAK2, p-STAT3, and collagen types I and III in the cardiac tissue of rats in the AS model group was increased compared with the normal group. In addition, vascular and myocardial degeneration, and necrosis were identified in the AS model group ([Fig. 5](#f5-mmr-21-03-1097){ref-type="fig"}). Compare with the AS model group, the expression levels of p-JAK2, p-STAT3, collagen types I and III were gradually restored in AS rats treated with urantide, which mainly exhibited perivascular and myocardial degeneration and necrosis. Moreover, this effect was positively associated with treatment time.

Discussion
==========

In the early stages of AS, type III collagen has been reported to have important compensatory effects on cardiac rearrangement and muscle bundle formation, which maintain the normal function of he tissue in the early stage of the disease ([@b19-mmr-21-03-1097],[@b20-mmr-21-03-1097]). However, in the advanced stages of AS, the accumulation of type I collagen in the myocardial interstitium occludes vasodilation and blood flow ([@b19-mmr-21-03-1097],[@b21-mmr-21-03-1097]). It was hypothesized that the effective regulation of disordered collagen metabolism may have important clinical significance in the treatment of AS.

The results demonstrated significant hyperlipidemia and myocardial hypertrophy, neutrophil infiltration, hyperemia and hemorrhage in the cardiac tissue of rats with AS, accompanied by abundant collagen. In addition, the UII/UT system in the cardiac tissue of rats with AS was activated. Luo *et al* ([@b22-mmr-21-03-1097]) found that UII induces the synthesis of type I collagen fibers and promotes the occurrence of myocardial fibrosis in rats. Previous studies performed by the same research group have reported that urantide had a protective effect on the thoracic aortas and livers of rats with AS following inhibition of the UII/UT system ([@b6-mmr-21-03-1097],[@b23-mmr-21-03-1097]). The possibility of urantide treatment having a reparative effect on disordered collagen metabolism caused by AS was further investigated in the present study.

AS was shown to induce JAK2/STAT3 pathway activation and MMP-2/TIMP-2 protein ratio imbalance, consequently causing disordered collagen metabolism mainly due to increased collagen type I/III expression. This finding is consistent with results from studies on cardiac pathology and similar to the results of current studies on myocardial fibrosis ([@b24-mmr-21-03-1097],[@b25-mmr-21-03-1097]). Ahn *et al* ([@b26-mmr-21-03-1097]) reported that the JAK2/STAT3 pathway may regulate MMP-2 expression, and promote endometrial cell proliferation and migration. Furthermore, it has been demonstrated that abnormal proliferation of cardiac fibroblasts causes an imbalance in the MMP-2/TIMP-2 protein ratio, leading to disordered collagen metabolism ([@b27-mmr-21-03-1097],[@b28-mmr-21-03-1097]). To investigate whether inhibition of the JAK2/STAT3 pathway would ameliorate the symptoms of myocardial fibrosis, rats with AS were treated with the peptide urantide.

Recent studies identified that contrast-enhanced cardiac magnetic resonance imaging of patients with AS indicated that individuals who had a history of cardiovascular events were more likely to present with myocardial fibrosis than those who did not ([@b29-mmr-21-03-1097],[@b30-mmr-21-03-1097]). In the present study, disordered collagen metabolism was significantly improved in rats with AS following treatment. This effect exhibited significant time dependence. To verify the mechanism of this effect, the UII/UT system and the JAK2/STAT3 pathway were examined, and it was determined that they had undergone significant changes. The results demonstrated that urantide effectively inhibited the expression of the UII/UT system and the JAK2/STAT3 pathway. Inhibition of the JAK2/STAT3 pathway may be associated with alleviated symptoms of myocardial fibrosis, as after urantide treatment the pathological symptoms of the heart were alleviated, which is consistent with reports from relevant studies ([@b7-mmr-21-03-1097],[@b22-mmr-21-03-1097]). It has been reported that simvastatin is capable of reducing myocardial fibrosis by downregulating related proteins, including transforming growth factor, MMP-2, MMP-9, TIMP-1 and TIMP-2 ([@b31-mmr-21-03-1097]). Nevertheless, studies on the relationship of simvastatin with the JAK2/STAT3 pathway are limited. Importantly, simvastatin was not found to inhibit the activation of the JAK2/STAT3 signaling pathway in the cardiac tissue of rats with AS. The results from the experiment in the present study are inconsistent with those observed following administration of simvastatin alone for the treatment of cardiac hypertrophy ([@b32-mmr-21-03-1097]). To this end, future studies should establish a rat model of myocardial fibrosis to further explore the association of simvastatin with the JAK2/STAT3 signaling pathway.

A recent study by Cho *et al* ([@b33-mmr-21-03-1097]) indicated that the JAK2/STAT3 pathway regulates MMP-2 expression, thus follow-up research was conducted on collagen mechanisms, such as changes in the expression levels of related MMPs and TIMPs after myocardial fibrosis. Another study by Wang *et al* ([@b25-mmr-21-03-1097]) demonstrated that an imbalance in the MMP-2/TIMP-2 protein ratio affected the synthesis and degradation of myocardial collagen. In the present study, an increase in MMP-2 expression was observed in rats with AS, whereas TIMP-2 expression was decreased. Treatment with urantide for a prolonged administration time resulted in a significant improvement in the MMP-2/TIMP-2 protein ratio. By contrast, the expression levels of collagen type I/III tended to decrease. The aforementioned findings indicated that the JAK2/STAT3 pathway affected the expression of collagen type I/III by regulating the balance of MMP-2/TIMP-2, thereby alleviating the symptoms of disordered collagen metabolism.

In addition, p-JAK2/p-STAT3 and collagen type I/III were abundantly expressed in AS lesions. Urantide treatment led to a decrease in the expression and range of these proteins. Moreover, their localization indicated that the JAK2/STAT3 pathway may be involved in the process of collagen metabolism.

In summary, the treatment of rats with AS with urantide was able to relieve cardiac symptoms and also significantly improve collagen metabolism. The underlying mechanism responsible for these effects may be antagonization of the UII/UT system and inhibition of the JAK2/STAT3 pathway by urantide. This combined mechanism is capable of regulating the balance between MMP-2/TIMP-2 and decreasing collagen type I/III expression. The regulation of collagen metabolism was restored and, consequently, the degree of myocardial fibrosis in rats with AS was reduced. In addition, differences were identified in the gene and protein expression levels of collagen I between the 3- and 7-day subgroups receiving urantide treatment. These differences could be considered an asynchronous phenomenon, with differences in expression time, related to the processes of transcription and/or translation. Regarding this matter, in-depth research should be conducted to clarify the relevant mechanisms. However, whether the UII/UT system directly affects the JAK2/STAT3 pathway and how this pathway regulates collagen metabolism remains unclear. The main limitation of the present study is the lack of *in vitro* cell experiments examining how the UII/UT system affects the JAK2/STAT3 signaling pathway and collagen metabolism. Therefore, the downstream genes regulated by the JAK2/STAT3 pathway that directly or indirectly affect collagen metabolism should be studied to further elucidate the mechanism by which the JAK2/STAT3 pathway affects collagen metabolism.
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![Experimental design. The setting of the experimental group, the interventions of each group and the intervention time. AS, atherosclerosis; w, weeks; d, days; n, number.](MMR-21-03-1097-g00){#f1-mmr-21-03-1097}

![Histological changes in the thoracic aortas of atherosclerotic rats induced by a high-fat diet identified by hematoxylin and eosin staining. In the normal group, the arterial intima was intact and smooth, and the cells were orderly arranged. In the AS model group, atherosclerotic plaque of the intima was present and the arrangement of the cells was disordered. Scale bars, 100 µm. AS, atherosclerosis.](MMR-21-03-1097-g01){#f2-mmr-21-03-1097}

![Alleviation of heart disease in rats with AS following urantide treatment. The following cardiac parameters improved with treatment time: (A) Pathological symptoms, (B) collagen expression, (C) cardiac pathological injury score, and (D) myocardial collagen volume. Scale bar, 50 µm. \*P\<0.05, \*\*P\<0.01 vs. the normal group; ^\#^P\<0.05, ^\#\#^P\<0.01 vs. the AS model group; ^\^^P\<0.05, ^\^\^^P\<0.01 vs. the simvastatin group. Data are presented as the mean ± SEM (n=6--8 rats in each group). H&E, hematoxylin & eosin; AS, atherosclerosis.](MMR-21-03-1097-g02){#f3-mmr-21-03-1097}

###### 

Effect of urantide on UII/GPR14, the JAK2/STAT3 pathway and collagen metabolism in the cardiac tissue of rats with AS. Changes in the expression of the following genes and proteins with increasing drug administration time: (A) relative expression level of genes. Changes in the expression of the following genes and proteins with increasing drug administration time: (B-a) relative expression level of signaling pathway proteins, (B-b) relative expression level of collagen metabolism related proteins and (C) MMP-2/TIMP-2 protein ratio. \*P\<0.05, \*\*P\<0.01 vs. the normal group; ^\#^P\<0.05, ^\#\#^P\<0.01 vs. the AS model group; ^\^^P\<0.05, ^\^\^^P\<0.01 vs. the simvastatin group. Data are presented as the mean ± SEM (n=6--8 rats in each group). AS, atherosclerosis; UII, urotensin II; G protein-coupled receptor 14; JAK2, Janus kinase 2; p, phosphorylated; STAT3, signal transducer and activator of transcription 3; MMP-2, matrix metalloproteinase 2; TIMP-2, TIMP metallopeptidase inhibitor 2.
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![Effect of urantide on the distribution and localization of p-JAK2/p-STAT3 and collagen type I/III. Immunofluorescence staining of: (A) p-JAK2, (B) p-STAT3, (C) collagen I and (D) collagen III indicating the location and intensity of the positive expression of these proteins in cardiac tissue derived from each group. Scale bars, 50 µm. Blue, nucleus; green, positive expression. AS, atherosclerosis; p-JAK2, phosphorylated-Janus kinase 2; p-STAT3, phosphorylated-signal transducer and activator of transcription 3.](MMR-21-03-1097-g06){#f5-mmr-21-03-1097}

###### 

Primer sequences used for the reverse transcription-quantitative PCR analysis of relative mRNA expression levels.

  Gene           Species   Primer sequence (5′→3′)
  -------------- --------- ------------------------------
  UII            Rat       F: GGAGGAGCTGGAGAGGACTG
                           R: GAGTCTCGGCACTGGGATCT
  GPR14          Rat       F: AATGGCTCTAGGGTCCTCCT
                           R: AACAGCCTCTGTGATGGACA
  JAK2           Rat       F: TTTGGATCCCTGGATACATACCTGA
                           R: TGGCACACACATTCCCATGA
  STAT3          Rat       F: TTTGAGACAGAGGTGTACCACCAAG
                           R: ACCACAGGATTGATGCCCAAG
  MMP-2          Rat       F: GGACAGTGACACCACGTGACAA
                           R: TTTCCAAAGTGCTGGCAGAATAGAC
  TIMP-2         Rat       F: GACACGCTTAGCATCACCCAGA
                           R: CTGTGACCCAGTCCATCCAGAG
  Collagen I     Rat       F: CCCTGCTGGAGAAGAAGGAA
                           R: AGGAGAACCTTTGGGACCAG
  Collagen III   Rat       F: ACTGGTGAACGTGGCTCTAA
                           R: GGACCTGGATGTCCACTTGA
  β-actin        Rat       F: CAGGCATTGCTGACAGGATG
                           R: TGCTGATCCACATCTGCTGG

UII, urotensin II; GPR14, G protein-coupled receptor 14; JAK2, Janus kinase 2; STAT3, signal transducer and activator of transcription 3; MMP-2, matrix metalloproteinase 2; TIMP-2, TIMP metallopeptidase inhibitor 2; F, forward; R, reverse.

###### 

Comparison of the levels of blood lipid components and Ca^2+^ in the sera of atherosclerotic and non-atherosclerotic rats.

  Group                TC (mmol/l)                                                                                                                                               TG (mmol/l)                                                                                                                                               HDL (mmol/l)                                                                                                                                              LDL (mmol/l)                                                                                                                                              Ca^2+^ (mmol/l)
  -------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------
  Normal               2.07±0.61                                                                                                                                                 0.28±0.08                                                                                                                                                 2.95±0.93                                                                                                                                                 0.27±0.05                                                                                                                                                 2.60±0.56
  AS model             11.18±3.12^[a](#tfn3-mmr-21-03-1097){ref-type="table-fn"}^                                                                                                0.77±0.12^[a](#tfn3-mmr-21-03-1097){ref-type="table-fn"}^                                                                                                 0.93±0.23^[a](#tfn3-mmr-21-03-1097){ref-type="table-fn"}^                                                                                                 1.70±0.31^[a](#tfn3-mmr-21-03-1097){ref-type="table-fn"}^                                                                                                 3.95±0.42^[a](#tfn3-mmr-21-03-1097){ref-type="table-fn"}^
  Simvastatin          4.06±1.51^[a](#tfn3-mmr-21-03-1097){ref-type="table-fn"},[b](#tfn4-mmr-21-03-1097){ref-type="table-fn"}^                                                  0.41±0.12^[b](#tfn4-mmr-21-03-1097){ref-type="table-fn"},[c](#tfn5-mmr-21-03-1097){ref-type="table-fn"}^                                                  2.16±0.35^[b](#tfn4-mmr-21-03-1097){ref-type="table-fn"},[c](#tfn5-mmr-21-03-1097){ref-type="table-fn"}^                                                  0.77±0.19^[a](#tfn3-mmr-21-03-1097){ref-type="table-fn"},[b](#tfn4-mmr-21-03-1097){ref-type="table-fn"}^                                                  3.63±0.13^[a](#tfn3-mmr-21-03-1097){ref-type="table-fn"},[d](#tfn6-mmr-21-03-1097){ref-type="table-fn"}^
  Urantide treatment                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
  3 days               7.52±1.59^[a](#tfn3-mmr-21-03-1097){ref-type="table-fn"},[b](#tfn4-mmr-21-03-1097){ref-type="table-fn"},[e](#tfn7-mmr-21-03-1097){ref-type="table-fn"}^   0.55±0.20^[a](#tfn3-mmr-21-03-1097){ref-type="table-fn"},[d](#tfn6-mmr-21-03-1097){ref-type="table-fn"},[f](#tfn8-mmr-21-03-1097){ref-type="table-fn"}^   1.48±0.37^[a](#tfn3-mmr-21-03-1097){ref-type="table-fn"},[b](#tfn4-mmr-21-03-1097){ref-type="table-fn"},[e](#tfn7-mmr-21-03-1097){ref-type="table-fn"}^   1.05±0.31^[a](#tfn3-mmr-21-03-1097){ref-type="table-fn"},[b](#tfn4-mmr-21-03-1097){ref-type="table-fn"},[e](#tfn7-mmr-21-03-1097){ref-type="table-fn"}^   3.46±0.32^[a](#tfn3-mmr-21-03-1097){ref-type="table-fn"},[d](#tfn6-mmr-21-03-1097){ref-type="table-fn"}^
  7 days               5.28±0.59^[a](#tfn3-mmr-21-03-1097){ref-type="table-fn"},[b](#tfn4-mmr-21-03-1097){ref-type="table-fn"},[f](#tfn8-mmr-21-03-1097){ref-type="table-fn"}^   0.37±0.15^[b](#tfn4-mmr-21-03-1097){ref-type="table-fn"}^                                                                                                 1.91±0.66^[a](#tfn3-mmr-21-03-1097){ref-type="table-fn"},[d](#tfn6-mmr-21-03-1097){ref-type="table-fn"}^                                                  0.84±0.27^[a](#tfn3-mmr-21-03-1097){ref-type="table-fn"},[b](#tfn4-mmr-21-03-1097){ref-type="table-fn"}^                                                  3.22±0.29^[a](#tfn3-mmr-21-03-1097){ref-type="table-fn"},[b](#tfn4-mmr-21-03-1097){ref-type="table-fn"},[f](#tfn8-mmr-21-03-1097){ref-type="table-fn"}^
  14 days              8.33±1.43^[a](#tfn3-mmr-21-03-1097){ref-type="table-fn"},[b](#tfn4-mmr-21-03-1097){ref-type="table-fn"},[e](#tfn7-mmr-21-03-1097){ref-type="table-fn"}^   0.59±0.21^[a](#tfn3-mmr-21-03-1097){ref-type="table-fn"},[f](#tfn8-mmr-21-03-1097){ref-type="table-fn"}^                                                  1.02±0.44^[a](#tfn3-mmr-21-03-1097){ref-type="table-fn"},[e](#tfn7-mmr-21-03-1097){ref-type="table-fn"}^                                                  1.27±0.27^[a](#tfn3-mmr-21-03-1097){ref-type="table-fn"},[b](#tfn4-mmr-21-03-1097){ref-type="table-fn"},[e](#tfn7-mmr-21-03-1097){ref-type="table-fn"}^   3.68±0.30^[a](#tfn3-mmr-21-03-1097){ref-type="table-fn"}^

TC, total cholesterol; TG, triglycerides; HDL, high-density lipoprotein; LDL, low-density lipoprotein; Ca^2+^, calcium. Differences between groups were detected by an automatic biochemical analyzer (mmol/l).

P\<0.01 vs. the normal group

P\<0.01 vs. the AS model group

P\<0.05 vs. the normal group

P\<0.05 vs. the AS model group

P\<0.01

P\<0.05 vs. the simvastatin group. Data are presented as the mean ± SEM (n=6--8 rats in each group).

[^1]: Contributed equally
